Biosynthetic and Synthetic Strategies for Assembling Capuramycin-Type Antituberculosis Antibiotics
Mycobacterium tuberculosis (Mtb) has recently surpassed HIV/AIDS as the leading cause of death by a single infectious agent. The standard therapeutic regimen against tuberculosis (TB) remains a long, expensive process involving a multidrug regimen, and the prominence of multidrug-resistant (MDR), extensively drug-resistant (XDR), and totally drug-resistant (TDR) strains continues to impede treatment success. An underexplored class of natural products—the capuramycin-type nucleoside antibiotics—have been shown to have potent anti-TB activity by inhibiting bacterial translocase I, a ubiquitous and essential enzyme that functions in peptidoglycan biosynthesis. The present review discusses current literature concerning the biosynthesis and chemical synthesis of capuramycin and analogs, seeking to highlight the potential of the capuramycin scaffold as a favorable anti-TB therapeutic that warrants further development.
Digital Object Identifier (DOI)
This research was funded by National Institutes of Health, grant number AI128862 and AI087849 and National Natural Science Foundation of China, grant numbers 81321004 and 81761128016.
Biecker, Ashley L.; Liu, Xiaodong; Thorson, Jon S.; Yang, Zhaoyong; and Van Lanen, Steven G., "Biosynthetic and Synthetic Strategies for Assembling Capuramycin-Type Antituberculosis Antibiotics" (2019). Pharmaceutical Sciences Faculty Publications. 144.
Published in Molecules, v. 24, issue 3, 433, p. 1-17.
© 2019 by the authors. Licensee MDPI, Basel, Switzerland.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).